Overview and History of WINIMED 10 (Stanozolol)

 

WINIMED 10 is the brand name for the anabolic steroid known as Stanozolol. WINIMED 10 (Stanozolol) is the third most popular anabolic steroid among bodybuilders and athletes. The first place belongs to DIANAMED 10 (Methandienone), while the second place is occupied by DECAMED 250 (Nandrolone Decanoate).

WINIMED 10 (Stanozolol) is famous thanks to its use by Canadian Olympic sprinter Ben Johnson in the 1988 Seoul Summer Olympic games where he tested positive for it. Stanozolol was first described in 1959 when it was introduced to the medical and scientific community. It was developed by Winthrop Laboratories in Great Britain, and Sterling in the USA ended up buying the patent in 1961 for the US market where it was branded as Winstrol.

Winstrol was approved for medical treatments, ranging from tissue and muscle wasting diseases to an Osteoporosis drug; it also was used in the treatment of burn victims and children with stunted growth. WINIMED 10 (Stanozolol) primary operation is through binding with the androgen receptor rather than non-receptor mediated activity, which is common with certain other anabolic steroids such as DIANAMED 10 (Methandienone) or ANADROMED 50 (Oxymetholone). WINIMED 10 (Stanozolol) also has a low affinity for binding with the Glucocorticoid-binding sites in addition to some activity that is independent of androgen receptors. Besides,WINIMED 10 (Stanozolol) possesses a very low degree of Progestogenic activity in the body.

WINIMED 10 (Stanozolol) is truly unique compound because of its ability to significantly lower SHBG (Sex Hormone Binding Globulin) levels in the body, allowing freer Testosterone and other anabolic hormones to be able to exert anabolic activity in muscle tissues. WINIMED 10 (Stanozolol) exhibits exceptional capability and a high degree of stimulating and facilitating protein synthesis, also it possesses a capability of boosting collagen synthesis in the body.

 

Chemical Characteristics of WINIMED 10 (Stanozolol)

WINIMED 10 (Stanozolol) chemical structure is very different from all other anabolic steroids. WINIMED 10 (Stanozolol) is a derivative of Dihydrotestosterone (DHT) where it contains a 3-2 Pyrazole group attached to the first cycloalkane ring (known as the A-ring) of the anabolic steroid structure. The Pyrazole group's attachment to the A-ring replaces the 3-keto group that usually sits in the same location. Because of this major modification, WINIMED 10 (Stanozolol) is classified as a Heterocyclic steroid. The Pyrazole group is responsible for WINIMED 10 (Stanozolol) stronger binding affinity for the androgen receptor in muscle tissue.

Being a DHT-derivative with modifications that separate its distinction with DHT, WINIMED 10 (Stanozolol) is more active in muscle tissue than DHT itself which is rendered inactive almost immediately by two enzymes upon its entrance into muscle tissue. All anabolic steroids that are part of the DHT-derivatives family (such as WINIMED 10 (Stanozolol), ANAVAMED 10 (Oxandrolone), PRIMOMED 100 (Methenolone Enanthate), Masteron, and others) contain modifications to their chemical structures that grant them significant activity and effectiveness within muscle tissue, where DHT itself unmodified would never survive metabolism there. WINIMED 10 (Stanozolol) contains the methyl group (also known as C17-alpha alkylation) to prevent it from being metabolized and broken down by the liver through oral ingestion.

 

 

 

Properties of WINIMED 10 (Stanozolol)

WINIMED 10 (Stanozolol) main mechanism of action is the binding with cellular androgen receptors. WINIMED 10 (Stanozolol) also contains some very small measurable form of anti-Progestogenic properties thanks to the Progesterone receptor. WINIMED 10 (Stanozolol) also possesses a low affinity for Glucocorticoid-binding site interactions, as well as activity that is independent of Androgen receptors, Progesterone receptors, and Glucocorticoid receptors.

 

WINIMED 10 (Stanozolol) possesses a very high binding affinity for SHBG (Sex Hormone Binding Globulin), this quality grants far more of WINIMED 10 (Stanozolol) to be free in the bloodstream in doing its job of signaling muscle growth (together with other anabolic steroids that may be stacked alongside it, such as Testosterone). SHBG is a protein that attaches and binds to other sex hormones (Testosterone, Estrogen, or any synthetic anabolic steroid) and renders them useless as long as SHBG is bound to that hormone. SHBG places ‘handcuffs’ on any hormone it binds to and not allowing it to do its job. WINIMED 10 (Stanozolol) has also demonstrated strong suppression of SHBG production in the body.

Being a DHT-derivative, WINIMED 10 (Stanozolol) is unable to bind with the aromatase enzyme, which is the huge benefit, because there will be no possible Estrogen conversion. Meaning, this compound doesn't have Estrogen-related side effects, such as water retention (and the associated risks of elevated blood pressure), and others. Being a DHT-derivative, it is also not able to interact with the 5-alpha-reductase enzyme, the enzyme which is responsible for the conversion of Testosterone into Dihydrotestosterone.

WINIMED 10 (Stanozolol) exhibits a longer half-life which is the result of its structural modifications, enabling its injectable format to possess a half-life of approximately 24 hours and 9 hours for the oral format.

WINIMED 10 (Stanozolol) holds an androgenic strength rating of 30 with an anabolic strength rating of 320, meaning it holds over three times the anabolic strength of Testosterone. Percentage-wise, it could be described that WINIMED 10 (Stanozolol) is 320% more anabolic than Testosterone, and it is 30% less androgenic than Testosterone. The injectable and oral formats of WINIMED 10 (Stanozolol) both possess the same chemical structure and are exactly 100% identical to each other. Usually, that is not like that.

All other anabolic steroids are different, where oral preparations are always C17-alpha alkylated, and injectable preparations are absent of this methylation (and often injectable compounds are also esterified to modulate the release rate and half-life). The result is a greater amount of hepatotoxicity (liver toxicity), and because both the injectable and oral preparations both possess the hepatotoxic modification of C17-alpha alkylation, they both will place an almost equal level of hepatotoxic strain on the liver. Anyway, the injectable format avoids the first-pass through the liver, which allows it to be slightly less hepatotoxic than the oral WINIMED 10 (Stanozolol) format.

 

WINIMED 10 (Stanozolol) Side Effects

 

Like any other steroid, WINIMED 10 (Stanozolol) also contains side effects, such as hepatic (liver) issues relating to hepatotoxicity, HPTA (Hypothalamic Pituitary Testicular Axis) disruption, and negative cardiovascular system impacts. WINIMED 10 (Stanozolol) is a DHT-derived anabolic steroid it cannot convert into Estrogen at any dose.

WINIMED 10 (Stanozolol) possesses a weaker androgenic strength rating comparing to Testosterone, but androgenic side effects can still appear to users who are especially sensitive to androgens. Androgenic side effects include increased oily skin and acne, hair growth on the body, MPB (male pattern baldness), and BPH (Benign Prostatic Hypertrophy). The use of a 5-alpha-reductase (5AR) inhibitor, such as Finasteride, Dutasteride, Proscar, or Propecia wouldn’t be effective because WINIMED 10 (Stanozolol)does not convert into DHT.

HPTA suppression and Hepatotoxicity (liver toxicity) are also concerns, which should be taken into account during the use of WINIMED 10 (Stanozolol). It is therefore recommended to use WINIMED 10 (Stanozolol), especially the oral variant, for periods of no longer than 6 – 8 weeks at a time. Cardiovascular health concerns are the major issue regarding WINIMED 10 (Stanozolol) side effects, as it can stimulate cardiac hypertrophy at even small dosages.

WINIMED 10 (Stanozolol) is infamous for producing very dangerous negative alterations in blood cholesterol levels, even with miniscule dosages of the oral format (as low as 6mg/day). Also, the injectable preparation of Stanozolol has demonstrated very negative implications for blood cholesterol.

 

WINIMED 10 (Stanozolol) Cycles and Use

WINIMED 10 (Stanozolol) cycles are normally held for fat loss, cutting, and pre-contest preparation where the end goal is to achieve very low body fat levels and a high level of definition in the physique. Some of the users utilize WINIMED 10 (Stanozolol) for bulking, mass and strength gaining, but there are other anabolic steroids which are the better choice for these purposes. WINIMED 10 (Stanozolol) cycles normally include a base compound of similar use, usually such as TESTOMED P 100 (Testosterone Propionate) for an 8 – 10-week cycle.

 

Intermediate and advanced WINIMED 10 (Stanozolol) cycles can involve three compounds in total, normally a stack such as TESTOMED P 100 (Testosterone Propionate), TRENBOMED A 100 (Trenbolone Acetate) and any format of WINIMED 10 (Stanozolol). It is very important to understand that because of the hepatotoxicity differences between the oral and injectable WINIMED 10 (Stanozolol)formats, it is possible to run its cycles longer with the injectable than the oral (8 – 10 weeks for the injectable and 6 – 8 weeks for the oral respectively).

 

Dosages and Administration of WINIMED 10 (Stanozolol)

WINIMED 10 (Stanozolol) is a very versatile anabolic steroid, and its dosages of the oral and injectable formats may vary extensively. In the medical field WINIMED 10 (Stanozolol) dosages usually are a 6mg per day, ideally split up throughout the day (e.g. a 2mg tablet administered 3 times per day). The injectable WINIMED 10 (Stanozolol) is typically prescribed at a dosage of 50mg only once every two to three weeks. In case WINIMED 10 (Stanozolol) is utilized for athletics and performance enhancement, such medical dosages and frequencies do not help at all.

For athletics, physique, and strength, WINIMED 10 (Stanozolol) dosages range (for injectable format) around 50 – 100mg administered every other day, equating to around 200 – 400mg per week. For oral WINIMED 10 (Stanozolol) format, the dosages are around 60mg per day, and lower dosages of WINIMED 10 (Stanozolol) (such as 25 – 50mg per day) are known to work well for all groups of users and athletes.

For female users, 5 – 10mg per day of the oral format of WINIMED 10 (Stanozolol) is known to be pretty common.  Such dosage is popular among female bodybuilders and athletes that want to avoid any risk of virilization and other unpleasant side effects. Although the injectable format of WINIMED 10 (Stanozolol) is not very popular among female athletes and bodybuilders, 15mg injected every other day (for an approximate total of 60mg per week) is a good recommendation.

 

DEUS MEDICAL

 

Chemical info / Information

Winstrol (AKA Stanozolol)
Chemical Name: 17β-Hydroxy-17-methyl-5alpha-androstano[3,2-c]pyrazole
Molecular Weight: 328.49 g/mol
Formula: C21H32N2O
Original Manufacturer: Winthrop Laboratories
Elimination half-life: 9 hours (oral), 24 hours (injectable)
Detection Time: 2 months
Anabolic Rating: 320
Androgenic Rating: 30